{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T01:13:17Z","timestamp":1785028397787,"version":"3.55.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1857,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1002\/hep.23696","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T19:03:12Z","timestamp":1269630192000},"page":"730-742","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":273,"title":["Standardization of nomenclature and causality assessment in drug\u2010induced liver injury"],"prefix":"10.1097","volume":"52","author":[{"given":"Robert J.","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Seeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-33-20250312","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"R2-33-20250312","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/hep.21095","article-title":"Drug\u2010induced liver injury: summary of a single topic clinical research conference","volume":"43","author":"Watkins","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R3-33-20250312","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug\u2010induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"R4-33-20250312","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs\u2014II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"R5-33-20250312","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.22442","article-title":"Reliability of the RUCAM for assessing causality in drug\u2010induced liver injury","volume":"48","author":"Rochon","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R6-33-20250312","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"R7-33-20250312","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Rationale, design and conduct of the Drug Induced Liver Injury Network prospective study","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"key":"R8-33-20250312","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","article-title":"Drug\u2010induced liver injury in a Swedish University hospital out\u2010patient hepatology clinic","volume":"24","author":"De Valle","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-33-20250312","first-page":"64","article-title":"The burden of acute non\u2010fulminant drug\u2010induced hepatitis in a United States tertiary referral center","volume":"39","author":"Galan","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"R10-33-20250312","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1572-0241.2006.01019.x","article-title":"Etiology of new\u2010onset jaundice: how often is it caused by idiosyncratic drug\u2010induced liver injury in the United States?","volume":"102","author":"Vuppalanchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R11-33-20250312","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":"Acute and clinically relevant drug\u2010induced liver injury: a population based case\u2010control study","volume":"58","author":"de Abajo","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R12-33-20250312","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug\u2010induced hepatic injuries: a French population\u2010based study","volume":"36","author":"Sgro","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R13-33-20250312","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug\u2010induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10\u2010year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"R14-33-20250312","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1478-3231.2007.01461.x","article-title":"Drug\u2010induced liver injury at an Asian center: a prospective study","volume":"27","author":"Wai","year":"2007","journal-title":"Liver Int"},{"key":"R15-33-20250312","first-page":"125","article-title":"Clinical characteristics of acute toxic liver injury","volume":"10","author":"Kim","year":"2004","journal-title":"Korean J Hepatol"},{"key":"R16-33-20250312","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1872-034X.2008.00486.x","article-title":"Drug\u2010induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006","volume":"39","author":"Takikawa","year":"2009","journal-title":"Hepatol Res"},{"key":"R17-33-20250312","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-92-1-14","article-title":"Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin","volume":"92","author":"Sharp","year":"1980","journal-title":"Ann Intern Med"},{"key":"R18-33-20250312","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.44.5.731","article-title":"The natural history of histologically proved drug induced liver disease","volume":"44","author":"Aithal","year":"1999","journal-title":"Gut"},{"key":"R19-33-20250312","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2008.10.021","article-title":"The long\u2010term follow\u2010up after idiosyncratic drug\u2010induced liver injury with jaundice","volume":"50","author":"Bjornsson","year":"2009","journal-title":"J Hepatol"},{"key":"R20-33-20250312","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case\u2010control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"R21-33-20250312","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1212\/WNL.37.3.379","article-title":"Valproic acid hepatic fatalities: a retrospective review","volume":"37","author":"Dreifuss","year":"1987","journal-title":"Neurology"},{"key":"R22-33-20250312","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.1840070130","article-title":"Reye's syndrome: current concepts","volume":"7","author":"Heubi","year":"1987","journal-title":"HEPATOLOGY"},{"key":"R23-33-20250312","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3949\/ccjm.66.4.239","article-title":"Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants","volume":"66","author":"Hamer","year":"1999","journal-title":"Cleve Clin J Med"},{"key":"R24-33-20250312","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1K522","article-title":"Abacavir hypersensitivity reaction: an update","volume":"42","author":"Hughes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R25-33-20250312","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA\u2010B*5701 genotype is a major determinant of drug\u2010induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"R26-33-20250312","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3748\/wjg.14.38","article-title":"Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive\u2010induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump","volume":"14","author":"Meier","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R27-33-20250312","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/adc.2007.122911","article-title":"Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1)","volume":"93","author":"McFarland","year":"2008","journal-title":"Arch Dis Child"},{"key":"R28-33-20250312","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10543409508835100","article-title":"Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting","volume":"5","author":"Tsong","year":"1995","journal-title":"J Biopharm Stat"},{"key":"R29-33-20250312","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yrtph.2009.03.003","article-title":"Drug\u2010induced liver injury following positive drug rechallenge","volume":"54","author":"Papay","year":"2009","journal-title":"Regul Toxicol Pharmacol"},{"key":"R30-33-20250312","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0029-1240005","article-title":"The pathology of drug\u2010induced liver disease","volume":"29","author":"Kleiner","year":"2009","journal-title":"Semin Liver Dis"},{"key":"R31-33-20250312","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R32-33-20250312","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","article-title":"Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug\u2010induced liver injury","volume":"27","author":"Garcia\u2010Cortes","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-33-20250312","first-page":"111","article-title":"Unexpected or toxic drug reaction assessment (imputation): actualization of the method used in France","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"key":"R35-33-20250312","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","article-title":"Development and validation of a clinical scale for the diagnosis of drug\u2010induced hepatitis","volume":"26","author":"Maria","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R36-33-20250312","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0168-8278(00)80127-0","article-title":"Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions","volume":"33","author":"Aithal","year":"2000","journal-title":"J Hepatol"},{"key":"R37-33-20250312","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2001.20645","article-title":"Comparison of two clinical scales for causality assessment in hepatotoxicity","volume":"33","author":"Lucena","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R38-33-20250312","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6346(02)00148-1","article-title":"Diagnosis of drug\u2010induced liver injury in Japanese patients by criteria of consensus meetings in Europe","volume":"25","author":"Masumoto","year":"2003","journal-title":"Hepatol Res"},{"key":"R39-33-20250312","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1386-6346(03)00232-8","article-title":"Assessment of 387 Japanese cases of drug induced liver injury by the diagnostic scale of the international consensus meeting","volume":"27","author":"Takikawa","year":"2003","journal-title":"Hepatol Res"},{"key":"R40-33-20250312","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00228-004-0869-2","article-title":"Agreement of expert judgment in causality assessment of adverse drug reactions","volume":"61","author":"Arimone","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R41-33-20250312","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MPG.0b013e3181709464","article-title":"Drug\u2010related hepatotoxicity and acute liver failure","volume":"47","author":"Murray","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R42-33-20250312","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Antituberculosis drug\u2010related liver dysfunction in chronic hepatitis B infection","volume":"31","author":"Wong","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R43-33-20250312","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"R44-33-20250312","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","article-title":"Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes","volume":"329","author":"Vuppalanchi","year":"2005","journal-title":"Am J Med Sci"},{"key":"R45-33-20250312","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0002-9343(91)90667-M","article-title":"Methotrexate and histologic hepatic abnormalities: a meta\u2010analysis","volume":"90","author":"Whiting\u2010O'Keefe","year":"1991","journal-title":"Am J Med"},{"key":"R46-33-20250312","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R48-33-20250312","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.0954-6820.1978.tb14900.x","article-title":"Adverse reactions with methyldopa\u2014a decade's reports","volume":"203","author":"Furhoff","year":"1978","journal-title":"Acta Med Scand"},{"key":"R49-33-20250312","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","article-title":"Intravenous n\u2010acetylcysteine improves spontaneous survival in early stage non\u2010acetaminophen acute liver failure","volume":"137","author":"Lee","year":"2009","journal-title":"Gastroenterology"},{"key":"R50-33-20250312","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug\u2010induced liver injury: the influence of age and gender","volume":"49","author":"Lucena","year":"2009","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23696","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201008000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:11:51Z","timestamp":1741777911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201008000-00033"}},"subtitle":["Summary of a clinical research workshop\u2020\u2021"],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23696","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}